Product Center

Further Advances in Orthopoxvirus mRNA Vaccines

Categories:Industry news
Author:
Origin:
Time of issue:2024-04-12
Views:

(Summary description)From April 2 to April 4, 2024, Dr. Xiong Nolin, Deputy General Manager of Yither Biotech (Shanghai) Co., Ltd., a wholly-owned subsidiary of Ab&B Bio-Tech Co., Ltd. (JS), was invited to participate in the World Vaccine Congress 2024, where he delivered a keynote speech and presented the results of the company's important R&D project on the Orthopoxvirus mRNA vaccine, which attracted great interest and recognition from international counterparts.

Further Advances in Orthopoxvirus mRNA Vaccines

Categories:Industry news
Author:
Origin:
Time of issue:2024-04-12 10:20
Views:

Information

From April 2 to April 4, 2024, Dr. Xiong Nolin, Deputy General Manager of Yither Biotech (Shanghai) Co., Ltd., a wholly-owned subsidiary of Ab&B Bio-Tech Co., Ltd. (JS), was invited to participate in the World Vaccine Congress 2024, where he delivered a keynote speech and presented the results of the company's important R&D project on the Orthopoxvirus mRNA vaccine, which attracted great interest and recognition from international counterparts.　　

On April 5, 2024, the research results were reviewed by international peer experts and published under the title "A Quadrivalent mRNA Immunization Elicits Potent Immune Responses against Multiple Orthopoxviral Antigens and Neutralization of Monkeypox Virus in Rodent Models" in Vaccines, an international journal of vaccinology; in addition, Ab&B Bio and Yither Bio jointly applied for a research project entitled "Monkeypox Virus mRNA Vaccine and Its Effectiveness". Also, a patent application jointly filed by Ab&B Bio and Yither Bio, entitled "Monkeypox Virus mRNA Vaccine and Its Use", was granted by the State Intellectual Property Office of the People's Republic of China (State Intellectual Property Office of China) on April 5, 2024.

Orthopoxviruses are a group of enveloped DNA viruses belonging to the Poxviridae family, which includes the smallpox virus that caused a global pandemic and the monkeypox virus that became endemic in 2022. Currently, there is a serious risk of monkeypox virus outbreaks, and other viruses in the Orthopoxvirus genus are also at risk of infecting humans. However, the efficacy of the existing smallpox vaccine against monkeypox needs to be further validated, and the current stockpile and production capacity of smallpox vaccines is extremely limited. In order to address the frequent emergence and potential pandemic of monkeypox and other orthopoxviruses, our technical team has designed and developed a new quadrivalent smallpox virus mRNA vaccine through in-depth research on smallpox virus, which has been proved to induce robust immune responses through animal immunization and can cross-react with multiple cognate proteins such as monkeypox virus and efficiently neutralize the monkeypox virus. In addition, the high level of neutralizing antibodies induced by this vaccine candidate in mice and rats was sustained, suggesting that it could be a good candidate for the prevention of monkeypox virus and other orthopoxvirus infections. Compared with the traditional design strategy of mixing multivalent mRNA antigens, the design strategy of encoding quadrivalent antigens with one mRNA by our team greatly simplifies the process development and reduces the cost of product development while maintaining the excellent pharmacodynamic properties of the vaccine, which provides a strong advantage in the industrialization of the vaccine in the future.

Scan the QR code to read on your phone

Previous: 2024 National Vaccine and Health Conference

Next: Zhang Xiaobing, a member of the Standing Committee of the Taizhou Municipal Party Committee and Secretary of the Party Working Committee of the Pharmaceutical High-tech Zone, visited the company for an investigation.

Previous: 2024 National Vaccine and Health Conference